- Report
- July 2024
- 288 Pages
Global
From €5287EUR$6,094USD£4,350GBP
- Report
- May 2025
- 967 Pages
Global
From €4444EUR$4,950USD£3,785GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- April 2025
- 150 Pages
Global
From €2918EUR$3,250USD£2,485GBP
€4355EUR$4,850USD£3,708GBP
- Report
- June 2025
- 67 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 190 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 182 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- December 2021
- 170 Pages
Global
€3457EUR$3,850USD£2,944GBP
- Report
- March 2024
- 97 Pages
Africa, Middle East
From €1347EUR$1,500USD£1,147GBP
The Long Acting Injectable (LAI) market is a segment of the medical device industry that focuses on the development and production of injectable drugs that are designed to provide sustained therapeutic effects over a longer period of time. LAI drugs are typically administered via intramuscular or subcutaneous injection, and are used to treat a variety of chronic conditions, including mental health disorders, diabetes, and cancer. LAI drugs are often preferred over oral medications due to their ability to provide more consistent and predictable therapeutic effects.
The LAI market is highly competitive, with a number of large pharmaceutical companies and medical device manufacturers vying for market share. Some of the major players in the LAI market include Pfizer, Novartis, Sanofi, Merck, and Johnson & Johnson. Show Less Read more